Hold still on Tesla after Cybercab debut flops
After Wall Street balked at Tesla‘s highly-anticipated robotaxi unveiling, CNBC’s Jim Cramer told investors not to make any moves on the stock. While he said he wouldn’t recommend buying Tesla …
After Wall Street balked at Tesla‘s highly-anticipated robotaxi unveiling, CNBC’s Jim Cramer told investors not to make any moves on the stock. While he said he wouldn’t recommend buying Tesla …
The Uber logo is seen in the rain in Krakow, Poland, on January 6, 2024. Klaudia Radecka | Nurphoto | Getty Images Tesla‘s hyped robotaxi unveiling posed a threat to Uber‘s …
Alphabet ‘s self-driving car unit Waymo is finally shifting into high gear. After years of heavy investment and losses, Waymo ridership is picking up momentum in its existing West Coast …
U.S. Vice President and Democratic presidential candidate Kamala Harris speaks at a campaign event at the Throwback Brewery, in North Hampton, New Hampshire, on September 4, 2024. Joseph Prezioso | …
Twenty years ago, as Morgan Stanley banker Michael Grimes was helping lead the public offering for the young company behind the Google search engine, one of the most anticipated of …
An Airbus A330-323 aircraft, operated by Delta Air Lines. Benoit Tessier | Reuters Delta Air Lines is the country’s most profitable airline. CEO Ed Bastian’s challenge is to make sure …
Trustly CEO Johan Tjarnberg. Trustly The boss of Swedish financial technology startup Trustly says an initial public offering for the company is still a year or two away from happening, …
CNBC’s Jim Cramer on Monday provided his take on four major stocks in the gig economy sector: Uber, Lyft, DoorDash and Instacart parent Maplebear. “After hearing from all of these …
CNBC’s Jim Cramer on Friday guided investors through the upcoming earnings-packed schedule on Wall Street, saying to focus on reports from companies such as Uber, Disney and Warner Bros. Discovery. …
There’s nothing like a moribund IPO market to create a pleasant backdrop for a bull run. We’ve had some small biotech deals and the usual SPAC junk. But nothing big, …